Chronic Kidney Disease Drugs Market Globally Grow at a CAGR of 1.21% by Revenue During the Forecast Period 2016-2019

About CKD

According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.
          
TechNavio's analysts forecast the Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.

Covered:

The Global CKD Drugs Market can be divided into two segments: Route of Administration which includes oral, SC, and IV and Mechanism of Action which includes ARBs, ACEIs, ESAs, PH Binders, and Vasodilators. This report covers the present scenario and the growth prospects of the Global CKD Drugs market for the period 2014–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CKD that are available in the market.

TechNavio's report, the Global CKD Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global CKD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=246173

Key Regions

    Americas
    EMEA       
    APAC

Key Vendors

    Actavis PLC
    Amgen Inc.
    Johnson & Johnson
    F. Hoffmann-La Roche Ltd
    Sanofi

Other Prominent Vendors

    Abbott Laboratories
    Akebia Therapeutics
    AMAG Pharmaceuticals
    Cara Therapeutics
    FibroGen
    Keryx Biopharmaceuticals
    Reata Pharmaceuticals
    OPKO Health

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG